Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Centanafadine QD XR in Children and Adolescents With ADHD (Japan-China Phase II/III)
CTR20254977Phase 3Active
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of centanafadine in attention deficit hyperactivity disorder (ADHD), sponsored by Otsuka Pharmaceutical Co., Ltd.. Started Dec 2025; status: active.
02
Drugs
centanafadine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on CTR20254977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254977.